金河生物子公司获得新兽药注册证书

Core Viewpoint - The approval of the inactivated vaccine for swine encephalitis by Jinhe Biotechnology's subsidiaries marks a significant advancement in the company's product offerings and enhances its position in the animal vaccine industry [1][2]. Group 1: Vaccine Development - Jinhe Biotechnology announced the approval of a new veterinary drug registration certificate for an inactivated vaccine against swine encephalitis, developed in collaboration with its subsidiaries and Beijing Huikang Yisheng Technology Co., Ltd [1]. - The inactivated vaccine is based on the A6-C strain isolated from infected pigs, providing better antigen matching and immunogenicity, and offering strong immune protection against currently circulating genotype I and III viruses [1]. Group 2: Industry Impact - The approval of the new vaccine is a result of the company's ongoing commitment to research and innovation, which will enhance its ability to provide comprehensive solutions to livestock customers [2]. - This development is expected to strengthen the company's market competitiveness and contribute positively to its sustainable development and research capabilities in the animal vaccine sector [2].